The alternative to EGFR inhibitors currently used in cancer therapy, particularly with intended use in combination with other therapeutic modalities, may be non-toxic products of natural origin, such as general tyrosine kinase inhibitor, genistein or its derivatives. The gene discussed is EGFR; the disease is cancer.